PYXS · Pyxis Oncology, Inc.
$3.08
-0.04 (-1.28%)
At close · Aug 21
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$256.90M
Shares
83.41M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
2,735,315 shares
as of 2022-09-30
· not restated in filings since 2022-11-01
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-11-26 | — | $150,000,000 | $150,000,000 as of 2026-06-30 | — | 10-Q , filed 2026-08-13 |
Key facts
CIK
1782223
CUSIP
747324101
13F (30d)
72 filings
72 filers
Visit website
Investor relations